

wherein Xaa3 is selected from the group consisting of aspartic acid, valine, cysteine, alanine, arginine, and serine;

with the proviso that when Xaa2 is valine, Xaa1 is tyrosine

and said peptide elicits a peptide-specific human CD8+ cytotoxic T

lymphocyte immune response.

11. The mutant ras peptide according to claim 10 wherein the peptide comprises an amino acid sequence of 13 amino acids.

12. The mutant ras peptide according to claim 10 wherein the peptide comprises an amino acid sequence of 10 amino acids.

25. A mutant ras peptide-carrier molecule conjugate comprising the mutant ras peptide according to claims 10-23 or 24 and a carrier molecule, said carrier molecule enhances the immunogenicity of the peptide.

27. An immunogen for eliciting a mutant ras peptide-specific human CD8+ cytotoxic T lymphocyte immune response comprising a mutant ras peptide according to claims 10-23 or 24 or combination thereof, said immunogen elicits a mutant ras peptide-specific human CD8+ cytotoxic T lymphocyte immune response.

32. A pharmaceutical composition comprising the mutant ras peptide of claims 10-24 and a pharmaceutically acceptable carrier.

33. The pharmaceutical composition according to claim 32, further comprising a biological response modifier.

34. The pharmaceutical composition according to claims 32 or 33, further comprising an adjuvant, a liposome formulation, or an antigen presenting cell.

Please add the following claims: